Clinical Research Directory

Inclusion Criteria: 1. Histologically proven prostate adenocarcinoma 2. Low or intermediate risk disease as defined by: * Low Risk: All of PSA\<10 ng/mL, Gleason Grade 6 AND Stage T1 or T2a * Intermediate Risk: Any or all of PSA 10-20 ng/mL, Gleason Grade 7 OR Stage T2b-c * Absence of high risk features (PSA\>20, T3-4, N1 or M1 disease, Gleason score 8-10) (PSA must be within 3 months prior to enrolment) 3. ECOG Performance status 0-2 4. Suitable for definitive external beam radiotherapy (IMRT or VMAT) 5. Ability to have three gold fiducial markers placed in the prostate 6. Six month course of androgen deprivation therapy allowed at clinician discretion. 7. Available for follow up for a minimum of 2 years (up to 3 years) Exclusion Criteria: 1. Lymph node irradiation 2. Any other systemic anti-prostate cancer therapy (i.e. non-ADT) both proven in the metastatic setting and investigational (e.g. docetaxel, enzalutamide) 3. Artificial hip(s) (Unable to visualise markers through prosthesis) 4. Prostate volume \> 90 cm3 measured from the CT scan 5. Patient lateral dimension \>40cm as measured at the level of the prostate from the CT scan 6. Suboptimal fiducial markers placement for treatment utilising KIM as assessed by a medical physicist by measuring marker positions from the CT scan 7. Fiducial migration or fewer than 3 fiducials present in the CT scan